PubMed Health⌕ Search

Biomedical subjects

I Krakowski

Publications and source records attributed to I Krakowski.

25 records · Page 2Linked to original sources
PubMed1993

Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.

BACKGROUND: Numerous preclinical and clinical trials showed that circadian-modified 5-fluoro-2-deoxyuridine (floxuridine; FUdR) infusion administered with a totally implantable programmable pump is associated with lower toxicity, higher dose intensity, and improved therapeutic outcome in renal cell carcinoma (RCC). METHODS: Between July 1988 and March 1991, the authors treated 30 patients with metastatic RCC with circadian-timed infusion FUdR at 0.15 mg/kg/day x 14 days at monthly intervals with a programmable portable pump. Time modification was simplified with one-third of the daily dose given between 11 p.m. and 11 a.m. and two-thirds given between 11 a.m. and 11 p.m. The characteristics of the patients were as follows: 19 men; 11 women; median age, 60 years (range, 28-82 years); median World Health Organization (WHO) performance status: 2 (range: 0-3); 77% failed prior systemic treatment. The main sites of tumor involvement were lungs (70%) and bone (53%). RESULTS: One hundred twenty-eight cycles were completed (median, 3 cycles per patient; range: 1-18 cycles per patient). Toxicity developed in 10 (33%) patients, primarily Grade 1-2 nausea/vomiting (6 patients), Grade 3 diarrhea (3 patients), and Grade 2 hand-foot syndrome (1 patient). In 28 patients evaluable for response, the authors observed four partial responses (14%; 95% confidence interval, 4-33%) and five stabilizations of the disease, including three minor responses. The median duration of response was 12 months (range, 8-24 months), and the median survival time was 6 months. CONCLUSION: Circadian continuous infusion FUdR may be an effective outpatient treatment for metastatic RCC, with low toxicity and good quality of life in responding patients.

Adult↗
PubMed1993

Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.

27 patients with metastatic colorectal carcinoma were treated, every 2 weeks, with 60 mg/m2 cystemustine, a new chloro-2-ethyl nitrosourea derivative. Haematological toxicity was the major side-effect including neutropenia and thrombocytopenia. We did not observe any complete or partial response. Cystemustine, with this dose and this schedule, has no activity in colorectal cancer.

Adolescent↗
PubMed1993

[Long term continuous combination of cisplatin and 5 fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients].

Seventy-seven pre-treated patients with advanced breast cancer were administered a combination chemotherapy with cisplatin 50 mg/sqm d1, 5-fluorouracil 300 mg/sqm/d protracted continuous infusion d1-d28, allopurinol 600 mg/d po d1-d28, q29d. Overall response rate was 26%, median survival time 46 weeks, survival rate 43.3% at 1 year, 20.2% at 2 years, 10.6% at 3 years. Response rate was rather high in CNS and meningeal involvement (6/10).

Adult↗
PubMed1991

[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection].

This pilot study was undertaken in a group of 7 patients receiving morphine either by oral route under a controlled release form (Moscontin tablets), or by subcutaneous route with continuous infusion. Complete pharmacokinetics over 24 h were carried out with blood samples taken every hour. The measurements of morphine and of its metabolite, morphine-6-glucuronide (M6G) were performed by high-performance liquid chromatography (HPLC) with coulometric detection, using nalorphine (NAL) as an internal standard. The morphinics were extracted on a Bond Elut C18 column according to a double liquid-solid extraction. The extract was chromatographed by ion-pairing on a mu Bondapak C18 column, 10 microns (300 x 3.9 mm). The minimal detectable concentrations were respectively 1 and 5 ng/ml for M and M6G. When Moscontin was given at dosages < 1 mg/kg/d, the areas under the curve over 24 h (AUC 24 h) of M were rather close to those of M6G (ratio 1.1 +/- 0.1). However, with dosages > 1 mg/kg/d, a difference appeared and gradually rose to a M/M6G ratio of 1.3 +/- 0.04. With subcutaneous infusion, the plasma levels of M6G were from 2 to 17-fold lower than those of M.

Administration, Oral↗
PubMed1988

[Surgical treatment of metastases of the humerus].

Surgical treatment of metastasis disease of the humerus was applied for 46 lesions among 42 patients, i-e 22% of overall osteosyntheses for skeletal metastasis. Two patients only are still alive at 3 and 4 years. The mean survival time is 8.1 months and at 3 months 50% died. Metastasis disease of the humerus becomes evident late during the evolution of the primary cancer, but 26% are revealing lesions. For 9.5% the primary tumor remains unknown. After review of the surgical methods generally used, indirect osteosynthesis by intra-medullary pinning according to Hackethal, without bone cement, is alleged. So the arm is immediately mobilized and a complementary irradiation is applied in post-operative. Prophylactic fixation of impending fractures is encouraged in order to suppress pain, and for better function. This paper demonstrates the changing concept of internal fixation of pathologic fractures and recommends intra-medullary nailing or pinning.

Adult↗